blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3342428

EP3342428 - ANTI-CANCER AGENT COMPRISING HVJ-E AND CXCL2 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.08.2021
Database last updated on 14.09.2024
FormerThe patent has been granted
Status updated on  11.09.2020
FormerGrant of patent is intended
Status updated on  11.05.2020
FormerRequest for examination was made
Status updated on  01.06.2018
FormerThe international publication has been made
Status updated on  04.03.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Osaka University
1-1 Yamadaoka
Suita-shi, Osaka 565-0871 / JP
For all designated states
GenomIdea Inc.
3-15, Edobori 1-chome
Nishi-ku
Osaka
550-0002 / JP
[2018/27]
Inventor(s)01 / KANEDA, Yasufumi
c/o OSAKA UNIVERSITY
1-1 Yamadaoka
Suita-shi Osaka 565-0871 / JP
02 / NAKAJIMA, Toshihiro
8-31 Midorigaoka 1-chome
Ikeda-shi Osaka 563-8577 / JP
 [2018/27]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2020/42]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2018/27]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date16839259.523.08.2016
[2018/27]
WO2016JP74464
Priority number, dateJP2015016460024.08.2015         Original published format: JP 2015164600
[2018/27]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017033912
Date:02.03.2017
Language:JA
[2017/09]
Type: A1 Application with search report 
No.:EP3342428
Date:04.07.2018
Language:EN
[2018/27]
Type: B1 Patent specification 
No.:EP3342428
Date:14.10.2020
Language:EN
[2020/42]
Search report(s)International search report - published on:JP02.03.2017
(Supplementary) European search report - dispatched on:EP27.02.2019
ClassificationIPC:A61K35/76, A61K38/19, A61P35/00
[2020/21]
CPC:
A61K35/76 (EP,US); A61K31/7088 (EP,US); A61K31/713 (EP,US);
A61K31/739 (EP,US); A61K38/19 (EP,US); A61K38/195 (EP,US);
A61K45/00 (EP,US); A61K48/00 (EP,US); A61P35/00 (US);
C12N7/00 (US); C12N2760/18833 (US); C12N2760/18871 (US) (-)
Former IPC [2018/27]A61K48/00, A61K31/7088, A61K31/713, A61K31/739, A61K35/76, A61K38/19, A61K45/00, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/27]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ANTIKREBSMITTEL MIT HVJ-E UND CXCL2[2018/27]
English:ANTI-CANCER AGENT COMPRISING HVJ-E AND CXCL2[2018/27]
French:AGENT ANTICANCÉREUX COMPRENANT LA HVJ-E ET LE CXCL2[2018/27]
Entry into regional phase27.02.2018Translation filed 
27.02.2018National basic fee paid 
27.02.2018Search fee paid 
27.02.2018Designation fee(s) paid 
27.02.2018Examination fee paid 
Examination procedure27.02.2018Examination requested  [2018/27]
27.02.2018Date on which the examining division has become responsible
12.09.2019Amendment by applicant (claims and/or description)
12.05.2020Communication of intention to grant the patent
08.09.2020Fee for grant paid
08.09.2020Fee for publishing/printing paid
08.09.2020Receipt of the translation of the claim(s)
Opposition(s)15.07.2021No opposition filed within time limit [2021/38]
Fees paidRenewal fee
10.08.2018Renewal fee patent year 03
15.08.2019Renewal fee patent year 04
13.08.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.08.2016
AL14.10.2020
AT14.10.2020
CY14.10.2020
CZ14.10.2020
DK14.10.2020
EE14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
MC14.10.2020
MK14.10.2020
MT14.10.2020
NL14.10.2020
PL14.10.2020
RO14.10.2020
RS14.10.2020
SE14.10.2020
SI14.10.2020
SK14.10.2020
SM14.10.2020
TR14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
[2024/41]
Former [2024/29]HU23.08.2016
AL14.10.2020
AT14.10.2020
CY14.10.2020
CZ14.10.2020
DK14.10.2020
EE14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
MC14.10.2020
MK14.10.2020
NL14.10.2020
PL14.10.2020
RO14.10.2020
RS14.10.2020
SE14.10.2020
SI14.10.2020
SK14.10.2020
SM14.10.2020
TR14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2024/22]HU23.08.2016
AL14.10.2020
AT14.10.2020
CY14.10.2020
CZ14.10.2020
DK14.10.2020
EE14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
MC14.10.2020
MK14.10.2020
NL14.10.2020
PL14.10.2020
RO14.10.2020
RS14.10.2020
SE14.10.2020
SI14.10.2020
SK14.10.2020
SM14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2023/30]HU23.08.2016
AL14.10.2020
AT14.10.2020
CY14.10.2020
CZ14.10.2020
DK14.10.2020
EE14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
MC14.10.2020
NL14.10.2020
PL14.10.2020
RO14.10.2020
RS14.10.2020
SE14.10.2020
SI14.10.2020
SK14.10.2020
SM14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2023/28]HU23.08.2016
AL14.10.2020
AT14.10.2020
CZ14.10.2020
DK14.10.2020
EE14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
MC14.10.2020
NL14.10.2020
PL14.10.2020
RO14.10.2020
RS14.10.2020
SE14.10.2020
SI14.10.2020
SK14.10.2020
SM14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2022/23]AL14.10.2020
AT14.10.2020
CZ14.10.2020
DK14.10.2020
EE14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
MC14.10.2020
NL14.10.2020
PL14.10.2020
RO14.10.2020
RS14.10.2020
SE14.10.2020
SI14.10.2020
SK14.10.2020
SM14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2022/18]AL14.10.2020
AT14.10.2020
CZ14.10.2020
DK14.10.2020
EE14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
MC14.10.2020
NL14.10.2020
PL14.10.2020
RO14.10.2020
RS14.10.2020
SE14.10.2020
SI14.10.2020
SK14.10.2020
SM14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
PT15.02.2021
Former [2022/10]AL14.10.2020
AT14.10.2020
CZ14.10.2020
DK14.10.2020
EE14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
NL14.10.2020
PL14.10.2020
RO14.10.2020
RS14.10.2020
SE14.10.2020
SI14.10.2020
SK14.10.2020
SM14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
PT15.02.2021
Former [2021/50]AL14.10.2020
AT14.10.2020
CZ14.10.2020
DK14.10.2020
EE14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
NL14.10.2020
PL14.10.2020
RO14.10.2020
RS14.10.2020
SE14.10.2020
SI14.10.2020
SK14.10.2020
SM14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2021/45]AL14.10.2020
AT14.10.2020
CZ14.10.2020
DK14.10.2020
EE14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
NL14.10.2020
PL14.10.2020
RO14.10.2020
RS14.10.2020
SE14.10.2020
SK14.10.2020
SM14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2021/37]AT14.10.2020
CZ14.10.2020
DK14.10.2020
EE14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
NL14.10.2020
PL14.10.2020
RO14.10.2020
RS14.10.2020
SE14.10.2020
SK14.10.2020
SM14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2021/36]AT14.10.2020
CZ14.10.2020
EE14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
NL14.10.2020
PL14.10.2020
RO14.10.2020
RS14.10.2020
SE14.10.2020
SK14.10.2020
SM14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2021/35]AT14.10.2020
CZ14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
NL14.10.2020
PL14.10.2020
RO14.10.2020
RS14.10.2020
SE14.10.2020
SK14.10.2020
SM14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2021/34]AT14.10.2020
CZ14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
NL14.10.2020
PL14.10.2020
RS14.10.2020
SE14.10.2020
SM14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2021/33]AT14.10.2020
FI14.10.2020
HR14.10.2020
LT14.10.2020
LV14.10.2020
NL14.10.2020
PL14.10.2020
RS14.10.2020
SE14.10.2020
SM14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2021/32]AT14.10.2020
FI14.10.2020
HR14.10.2020
LV14.10.2020
NL14.10.2020
PL14.10.2020
RS14.10.2020
SE14.10.2020
SM14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2021/30]AT14.10.2020
FI14.10.2020
HR14.10.2020
LV14.10.2020
NL14.10.2020
PL14.10.2020
RS14.10.2020
SE14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2021/28]AT14.10.2020
FI14.10.2020
HR14.10.2020
LV14.10.2020
PL14.10.2020
RS14.10.2020
SE14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2021/25]AT14.10.2020
FI14.10.2020
LV14.10.2020
PL14.10.2020
RS14.10.2020
SE14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
IS14.02.2021
PT15.02.2021
Former [2021/24]AT14.10.2020
FI14.10.2020
LV14.10.2020
RS14.10.2020
SE14.10.2020
BG14.01.2021
NO14.01.2021
GR15.01.2021
PT15.02.2021
Former [2021/23]FI14.10.2020
LV14.10.2020
RS14.10.2020
SE14.10.2020
NO14.01.2021
GR15.01.2021
PT15.02.2021
Former [2021/22]FI14.10.2020
RS14.10.2020
NO14.01.2021
PT15.02.2021
Former [2021/21]FI14.10.2020
PT15.02.2021
Former [2021/20]FI14.10.2020
Documents cited:Search[Y]  - Toshihiro Nakajima ET AL, "A Novel Therapy for Melanoma and Prostate Cancer Using a Non-Replicating Sendai Virus Particle (HVJ-E)", Novel Gene Therapy Approaches, InTech, (20130213), doi:10.5772/55014, ISBN 978-953-51-0966-2, XP055558262 [Y] 1,4-7,10,11 * page 158, paragraphs 1-4 page 164, paragraph 5-page 165, paragraph 3;; figures 2, 4 *

DOI:   http://dx.doi.org/10.5772/55014
 [Y]  - JIANG QUN ET AL, "IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, US, (20080701), vol. 31, no. 6, doi:10.1097/CJI.0B013E31817D8E75, ISSN 1524-9557, pages 555 - 562, XP008124665 [Y] 1,4-7,10,11 * abstract;; figure 1 *

DOI:   http://dx.doi.org/10.1097/CJI.0b013e31817d8e75
 [Y]  - FUJIMURA TAKU ET AL, "Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY VCH, WEINHEIM, (20061201), vol. 36, no. 12, doi:10.1002/EJI.200636053, ISSN 0014-2980, pages 3371 - 3380, XP002595703 [Y] 1,4-7,10,11 * abstract;; figures 1-3,6 *

DOI:   http://dx.doi.org/10.1002/EJI.200636053
 [XP]  - CHIN YANG CHANG ET AL, "Virus-stimulated neutrophils in the tumor microenvironment enhance T cell-mediated anti-tumor immunity", ONCOTARGET, (20160705), vol. 7, no. 27, doi:10.18632/oncotarget.9743, page 27, XP055558327 [XP] 1-11 * abstract *

DOI:   http://dx.doi.org/10.18632/oncotarget.9743
International search[YA]  - KAWAGUCHI YOSHIFUMI et al., "Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle", International journal of cancer, (20090000), vol. 124, no. 10, pages 2478 - 87, XP055515585 [Y] 1-4, 6, 12, 14, 16 * See FIGURE 6 * [A] 5, 7-11, 13, 15, 17

DOI:   http://dx.doi.org/10.1002/ijc.24234
 [YA]  - MASAKI NAKAHARA et al., "Effect of Lipopolysaccharide from Proteusmirabilis, alone or with Antitumor Agents, against Experimental Animal Tumors", Agricultural and Biological Chemistry, (19760000), vol. 40, no. 6, pages 1201 - 1208, XP 055372602 [Y] 1-4, 6, 12, 14, 16 * See Fig. 6 * [A] 7-11, 13, 15, 17
 [YA]  - TSUTSUMI Y. et al., "Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency", British journal of cancer, (19950000), vol. 71, no. 5, pages 963 - 968, XP 009006142 [Y] 1-4, 6, 12, 14, 16 * See Table II * [A] 7-11, 13, 15, 17
 [A]  - DON D. MICKEY et al., "Effects of the immunomodulator PSK on growth of human prostate adenocarcinoma in immunodeficient mice", International journal of immunopharmacology, (19890000), vol. 11, no. 7, doi:doi:10.1016/0192-0561(89)90137-9, pages 829 - 38, XP 023812513 [A] 5, 7-11, 13, 15, 17 * See Fig. 1 *
 [A]  - ZVI G. FRIDLENDER et al., "Polarization of tumor-associated neutrophil phenotype by TGF- beta: ''N1'' versus ''N2'' TAN", Cancer cell, (20090000), vol. 16, no. 3, pages 183 - 94, XP 055372607 [A] 7-11, 13, 15, 17 * See Summary *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.